Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy

被引:37
|
作者
Ballo, Olivier [1 ,2 ]
Tarazzit, Ikram [1 ]
Stratmann, Jan [1 ]
Reinheimer, Claudia [3 ,4 ]
Hogardt, Michael [3 ,4 ]
Wichelhaus, Thomas A. [3 ,4 ]
Kempf, Volkhard [3 ,4 ]
Serve, Hubert [1 ,2 ,4 ]
Finkelmeier, Fabian [2 ,5 ]
Brandts, Christian [1 ,2 ]
机构
[1] Goethe Univ Hosp, Dept Med, Hematol Oncol, Frankfurt, Germany
[2] Goethe Univ Hosp, Univ Canc Ctr Frankfurt UCT, Frankfurt, Germany
[3] Goethe Univ Hosp, Inst Med Microbiol & Infect Control, Frankfurt, Germany
[4] Goethe Univ Hosp, Univ Ctr Infect Dis, Frankfurt, Germany
[5] Goethe Univ Frankfurt, Dept Med Gastroenterol Hepatol & Endocrinol, Frankfurt, Germany
来源
PLOS ONE | 2019年 / 14卷 / 01期
关键词
BLOOD-STREAM INFECTIONS; HIGH-RISK PATIENTS; HEMATOLOGICAL MALIGNANCIES; KLEBSIELLA-PNEUMONIAE; ENTEROBACTERIACEAE; IMPACT; RECOMMENDATIONS; NEUTROPENIA; THERAPY; SOCIETY;
D O I
10.1371/journal.pone.0210991
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction The global spread of multidrug-resistant organisms (MDRO) complicates treatment and isolation measures in hospitals and has shown to increase mortality. Patients with disease- or therapy-related immunodeficiency are especially at risk for fatal infections caused by MDRO. The impact of MDRO colonization on the clinical course of AML patients undergoing intensive induction chemotherapy a potentially curative but highly toxic treatment option- has not been systematically studied. Materials & methods 312 AML patients undergoing intensive induction chemotherapy between 2007 and 2015 were examined for MDRO colonization. Patients with evidence for MDRO before or during the hospital stay of induction chemotherapy were defined as colonized, patients who never had a positive swab for MDRO were defined as noncolonized. Results Of 312 AML patients 90 were colonized and 130 were noncolonized. Colonized patients suffered from significantly more days with fever, spent more days on the intensive care unit and had a higher median C-reactive protein value during the hospital stay. These findings did not result in a prolonged length of hospital stay or an increased mortality rate for colonized patients. However, in a subgroup analysis, patients colonized with carbapenem-resistant enterobacteriaceae (CRE) had a significantly reduced 60- and 90-day, as well as 1- and 2-year survival rates when compared to noncolonized patients. Conclusion Our analysis highlights the importance of intensive MDRO screening especially in patients with febrile neutropenia since persisting fever can be a sign of MDRO-colonization. CRE-colonized patients require special surveillance, since they seem to be at risk for death.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] ICU intervention during induction chemotherapy for adult patients with newly diagnosed acute myeloid leukemia
    Hartsock, Bobbi
    Lim, Matthew J.
    Roth, Christine Garcia
    Raptis, Nepheli
    Weber, David
    Sehgal, Alison
    Boyiadzis, Michael
    Raptis, Anastasios
    Hou, Jing-Zhou
    Im, Annie
    Dorritie, Kathleen
    Marks, Stanley
    Agha, Mounzer
    Lim, Seah H.
    LEUKEMIA RESEARCH, 2016, 48 : 16 - 19
  • [42] A pilot randomized study for optimal red cell transfusion in acute myeloid leukemia patients with intensive chemotherapy
    Byun, Ja Min
    Park, Woochan
    Shin, Dong-Yeop
    Koh, Youngil
    Kim, Inho
    Yoon, Sung -Soo
    Park, Jae Hyeon
    Kim, Hyungsuk
    Hong, Junshik
    BLOOD TRANSFUSION, 2023, 21 (06) : 479 - 487
  • [43] Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes
    Buckley, Sarah A.
    Othus, Megan
    Vainstein, Vladimir
    Abkowitz, Janis L.
    Estey, Elihu H.
    Walter, Roland B.
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (04) : 423 - 428
  • [44] Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy
    Shallis, Rory M.
    Stahl, Maximilian
    Wei, Wei
    Montesinos, Pau
    Lengline, Etienne
    Neukirchen, Judith
    Bhatt, Vijaya R.
    Sekeres, Mikkael A.
    Fathi, Amir T.
    Konig, Heiko
    Luger, Selina
    Khan, Irum
    Roboz, Gail J.
    Cluzeau, Thomas
    Martinez-Cuadron, David
    Raffoux, Emmanuel
    Germing, Ulrich
    Umakanthan, Jayadev Manikkam
    Mukhereje, Sudipto
    Brunner, Andrew M.
    Miller, Adam
    McMahon, Christine M.
    Ritchie, Ellen K.
    Rodriguez-Veiga, Rebeca
    Itzykson, Raphael
    Boluda, Blanca
    Rabian, Florence
    Tormo, Mar
    Cruz, Evelyn Acuna
    Rabinovich, Emma
    Yoo, Brendan
    Cano, Isabel
    Podoltsev, Nikolai A.
    Bewersdorf, Jan Philipp
    Gore, Steven
    Zeidan, Amer M.
    LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1220 - 1225
  • [45] Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia
    Fathi, Amir T.
    Wander, Seth A.
    Blonquist, Traci M.
    Brunner, Andrew M.
    Amrein, Philip C.
    Supko, Jeffrey
    Hermance, Nicole M.
    Manning, Amity L.
    Sadrzadeh, Hossein
    Ballen, Karen K.
    Attar, Eyal C.
    Graubert, Timothy A.
    Hobbs, Gabriela
    Joseph, Christelle
    Perry, Ashley M.
    Burke, Meghan
    Silver, Regina
    Foster, Julia
    Bergeron, Meghan
    Ramos, Aura Y.
    Som, Tina T.
    Fishman, Kaitlyn M.
    McGregor, Kristin L.
    Connolly, Christine
    Neuberg, Donna S.
    Chen, Yi-Bin
    HAEMATOLOGICA, 2017, 102 (04) : 719 - 727
  • [46] The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia
    Ciftciler, Rafiye
    Haznedaroglu, Ibrahim C.
    Sayinalp, Nilgun
    Ozcebe, Osman
    Aksu, Salih
    Demiroglu, Haluk
    Goker, Hakan
    Malkan, Umit Yavuz
    Buyukasik, Yahya
    TURKISH JOURNAL OF HEMATOLOGY, 2020, 37 (02) : 116 - 120
  • [47] Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia
    Bertoli, Sarah
    Berard, Emilie
    Huguet, Francoise
    Huynh, Anne
    Tavitian, Suzanne
    Vergez, Francois
    Dobbelstein, Sophie
    Dastugue, Nicole
    Mansat-De Mas, Veronique
    Delabesse, Eric
    Duchayne, Eliane
    Demur, Cecile
    Sarry, Audrey
    Lauwers-Cances, Valerie
    Laurent, Guy
    Attal, Michel
    Recher, Christian
    BLOOD, 2013, 121 (14) : 2618 - 2626
  • [48] Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia
    Maurillo, Luca
    Buccisano, Francesco
    Spagnoli, Alessandra
    Voso, Maria Teresa
    Fianchi, Luana
    Papayannidis, Cristina
    Gaidano, Gian Luca
    Breccia, Massimo
    Musto, Pellegrino
    De Bellis, Eleonora
    Del Principe, Maria Ilaria
    Lunghi, Monia
    Lessi, Federica
    Martinelli, Giovanni
    Venditti, Adriano
    ANNALS OF HEMATOLOGY, 2018, 97 (10) : 1767 - 1774
  • [49] The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia
    Nakano, Hirofumi
    Fujiwara, Shin-ichiro
    Ito, Shoko
    Mashima, Kiyomi
    Umino, Kento
    Minakata, Daisuke
    Yamasaki, Ryoko
    Kawasaki, Yasufumi
    Sugimoto, Miyuki
    Ashizawa, Masahiro
    Yamamoto, Chihiro
    Hatano, Kaoru
    Okazuka, Kiyoshi
    Sato, Kazuya
    Oh, Iekuni
    Ohmine, Ken
    Suzuki, Takahiro
    Muroi, Kazuo
    Kanda, Yoshinobu
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (03) : 357 - 364
  • [50] Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy
    Boyiadzis, Michael
    Redner, Robert L.
    Raptis, Anastasios
    Hou, Jing-Zhou
    Agha, Mounzer
    Foon, Kenneth A.
    ANNALS OF HEMATOLOGY, 2011, 90 (06) : 733 - 735